|
Sep 30
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
|
Sep 28
|
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
|
|
Sep 28
|
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
|
|
Sep 27
|
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
|
|
Sep 27
|
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
|
|
Sep 27
|
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
|
|
Sep 27
|
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
|
|
Sep 27
|
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
|
|
Sep 27
|
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
|
|
Sep 27
|
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
|
|
Sep 27
|
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
|
|
Sep 27
|
FDA, after delay, clears Regeneron and Sanofi drug for COPD
|
|
Sep 26
|
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
|
|
Sep 25
|
Amgen Stock Falls on Disappointing Drug Data
|
|
Sep 24
|
US Equity Indexes Rise as Sliding Consumer Confidence Undermines Bowman's Call for Policy Caution
|
|
Sep 24
|
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
|
|
Sep 24
|
Regeneron slump continues as analysts turn more cautious
|
|
Sep 24
|
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
|
|
Sep 23
|
Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says
|
|
Sep 23
|
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
|